Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02589366 · ClinicalTrials.gov registry record · Phase 1
Lymphoseek as Lymphoid Tissue Targeting Agent in Patients With Cancer of the Endometrium
A Phase 1 study, sponsored by University of California, San Diego.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02589366 is a Phase 1 study that was terminated before completion, run by University of California, San Diego. The registered enrollment target is 2 participants.
The verdict
NCT02589366, a Phase 1 study, was terminated before completion, sponsored by University of California, San Diego.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
Part of standard treatment for endometrial cancer is to remove one or more groups of lymph nodes (lymph node dissection). Lymph nodes are small, bean-shaped organs located within the body throughout the lymphatic system (the tissues and organs involved in immunity, which aids in the fight against infection and cancer). The purpose of this study is to compare the safety and ability of Lymphoseek and a Vital Blue Dye (tracing agent) to find lymph nodes that may carry cancer from the tumor through the lymphatic system. Lymphoseek will be injected into the tumor on the day before surgery to remove lymph nodes. Vital Blue Dye will be administered during surgery to trace the cancer as well. The surgeon will remove the lymph nodes as part of routine surgery and will keep track of which lymph nodes are identified by Lymphoseek and Vital Blue Dye. These nodes will be sent to another doctor to view them under a microscope and see if the nodes contain cancer cells. The hypothesis is that Lymphoseek can be used safely and will be at least as effective as blue dye in identifying the lymph nodes that may have cancer cells.
Interventions
- DRUG Lymphoseek plus Vital Blue Dye
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-11 |
| Est. Completion | 2018-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02589366
The ClinicalTrials.gov registry entry for NCT02589366 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lymphoseek plus Vital Blue Dye is the first listed.
NCT02589366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02589366 about?
NCT02589366 is a clinical study titled "Lymphoseek as Lymphoid Tissue Targeting Agent in Patients With Cancer of the Endometrium". Part of standard treatment for endometrial cancer is to remove one or more groups of lymph nodes (lymph node dissection). Lymph nodes are small, bean-shaped organs located within the body throughout the lymphatic system (the tissues and organs involved in immunity, which aids in the fight against in...
What is the current status of trial NCT02589366?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2015-11. Estimated completion is 2018-04.
What interventions are being tested in trial NCT02589366?
The interventions under investigation include: Lymphoseek plus Vital Blue Dye (DRUG).
Who is sponsoring clinical trial NCT02589366?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.